PL2252148T3 - Sposoby leczenia zespołu jelita drażliwego - Google Patents

Sposoby leczenia zespołu jelita drażliwego

Info

Publication number
PL2252148T3
PL2252148T3 PL09715020T PL09715020T PL2252148T3 PL 2252148 T3 PL2252148 T3 PL 2252148T3 PL 09715020 T PL09715020 T PL 09715020T PL 09715020 T PL09715020 T PL 09715020T PL 2252148 T3 PL2252148 T3 PL 2252148T3
Authority
PL
Poland
Prior art keywords
methods
bowel syndrome
irritable bowel
treating irritable
treating
Prior art date
Application number
PL09715020T
Other languages
English (en)
Inventor
William Forbes
Lorin Johnson
Original Assignee
Salix Pharmaceuticals, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41016472&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2252148(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Salix Pharmaceuticals, Ltd. filed Critical Salix Pharmaceuticals, Ltd.
Publication of PL2252148T3 publication Critical patent/PL2252148T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL09715020T 2008-02-26 2009-02-26 Sposoby leczenia zespołu jelita drażliwego PL2252148T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3167908P 2008-02-26 2008-02-26
US10280108P 2008-10-03 2008-10-03
EP09715020.5A EP2252148B1 (en) 2008-02-26 2009-02-26 Methods for treating irritable bowel syndrome
PCT/US2009/035348 WO2009108814A1 (en) 2008-02-26 2009-02-26 Methods for treating bowel diseases

Publications (1)

Publication Number Publication Date
PL2252148T3 true PL2252148T3 (pl) 2019-09-30

Family

ID=41016472

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09715020T PL2252148T3 (pl) 2008-02-26 2009-02-26 Sposoby leczenia zespołu jelita drażliwego

Country Status (15)

Country Link
US (3) US8309569B2 (pl)
EP (2) EP2252148B1 (pl)
KR (1) KR20100122937A (pl)
CN (1) CN101959412A (pl)
AU (1) AU2009219240B2 (pl)
BR (1) BRPI0908026B8 (pl)
CA (2) CA2716578A1 (pl)
DK (1) DK2252148T3 (pl)
ES (1) ES2727728T3 (pl)
MX (1) MX2010009197A (pl)
NZ (1) NZ587098A (pl)
PL (1) PL2252148T3 (pl)
PT (1) PT2252148T (pl)
RU (2) RU2519649C2 (pl)
WO (1) WO2009108814A1 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US20110065741A1 (en) * 2009-02-26 2011-03-17 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (ibs)
BRPI0908026B8 (pt) 2008-02-26 2021-05-25 Salix Pharmaceuticals Ltd uso de rifaximina no tratamento de doenças do intestino
US11779571B2 (en) 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
HRP20200284T1 (hr) 2008-10-02 2020-07-10 Salix Pharmaceuticals, Ltd. Postupci liječenja hepatičke encefalopatije
WO2010093776A1 (en) * 2009-02-11 2010-08-19 Cedars-Sinai Medical Center Antibiotic therapy to reduce the likelihood of developing post-infectious irritable bowel syndrome
ES2656850T3 (es) 2009-02-11 2018-02-28 Cedars-Sinai Medical Center Diagnóstico del síndrome intestinal inflamatorio con base en la toxina de distensión citoletal
AU2011218129A1 (en) * 2010-02-18 2012-08-23 Board Of Regents Of The University Of Texas System Methods for treating infection
PH12013500082B1 (en) * 2010-07-12 2019-06-28 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
EP2773205B1 (en) * 2011-11-02 2024-05-22 Salix Pharmaceuticals, Inc. Rifaximin for retreating diarrhea-predominant irritable bowel syndrome
KR101394197B1 (ko) * 2012-08-17 2014-05-30 관동대학교산학협력단 염증성 장 질환과 연관된 단일염기다형성 정보를 제공하는 방법
US20150223747A1 (en) * 2012-09-06 2015-08-13 Alvine Pharmaceuticals, Inc. Patient reported outcome instrument
CN104955457A (zh) * 2012-09-12 2015-09-30 萨利克斯药品公司 给予利福昔明而不产生抗生素耐药性的方法
HK1212555A1 (zh) * 2012-09-13 2016-06-17 Salix Pharmaceuticals, Inc. 改善患有肝性腦病的受試者的長期生存和降低其再住院率的方法
AU2013315981B2 (en) 2012-09-17 2019-04-18 Cedars-Sinai Medical Center Diagnosis and treatment of motility disorders of the gut and bladder, and of fibromyalgia
EA032705B1 (ru) * 2013-04-12 2019-07-31 Альфасигма С.П.А. Способ лечения или предупреждения энтеропатии
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
WO2015171493A1 (en) 2014-05-04 2015-11-12 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
DK3546464T3 (da) 2014-05-12 2020-07-27 Alfasigma Spa Fremstilling og anvendelse af den krystallinske form tau af rifaximin solvateret med degme
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
RU2605615C2 (ru) * 2014-07-15 2016-12-27 Общество с ограниченной ответственностью "Гелизовит" Ректальный поликомплексный гель для лечения язвенного колита, болезни крона, свищей и осложнений, вызванных этими заболеваниями
EA039096B1 (ru) * 2014-08-11 2021-12-03 Саликс Фармасьютикалз, ИНК. Способы лечения заболевания кишечника (срк)
JP7027412B2 (ja) 2016-09-30 2022-03-01 サリックス ファーマスーティカルズ,インコーポレーテッド リファキシミンの固体分散体の形態
EP3573650A4 (en) 2017-01-30 2020-12-09 Cedars-Sinai Medical Center DIAGNOSIS OF SCLERODERMIA
RU2665945C1 (ru) * 2017-08-07 2018-09-05 Наталья Юрьевна Пшеничная Способ прогнозирования длительности диареи и выбора тактики лечения
EP4438039A3 (en) 2017-11-10 2024-12-04 Cosmo Technologies Ltd. Oral rifamycin sv compositions
WO2019209942A1 (en) * 2018-04-24 2019-10-31 Cedars-Sinai Medical Center Methods and systems for characterizing severe crohn's disease
RU2712943C1 (ru) * 2018-08-03 2020-02-03 Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения города Москвы Способ профилактики туберкулеза при воспалительных заболеваниях кишечника
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
BR112022003500A2 (pt) 2019-09-24 2022-05-24 Bausch Health Ireland Ltd Formulações líquidas de rifaximina
US20230116647A1 (en) 2020-03-24 2023-04-13 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
JP7825575B2 (ja) 2020-06-26 2026-03-06 バウシュ ヘルス アイルランド リミテッド 標的化放出リファキシミン組成物
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease
EP4412588A1 (en) * 2021-10-05 2024-08-14 Cosmo Technologies Ltd An in-situ gelling enema of rifamycin for treating pouchitis and distal ulcerative colitis
EP4162928A1 (en) * 2021-10-05 2023-04-12 Cosmo Technologies Ltd. Rifamycin for the treatment of pouchitis, with an in-situ gelling formulation
WO2024076257A2 (en) 2022-10-03 2024-04-11 Dikovskiy Alexander Vladimirovich Composition for treatment of diarrhea of bacterial, viral and bacterial and functional origins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3167909A (en) 1961-04-24 1965-02-02 Thompson Ramo Wooldridge Inc Self-cooled rocket nozzle
US3132908A (en) 1962-04-02 1964-05-12 Carrier Corp Thrust bearing construction
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20060154276A1 (en) 2004-05-13 2006-07-13 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
EP1855680A2 (en) * 2005-02-25 2007-11-21 Solvay Pharmaceuticals, Inc. Method of treatment of diarrhea-predominant ibs in a female subject receiving contraceptive therapy
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
BRPI0908026B8 (pt) 2008-02-26 2021-05-25 Salix Pharmaceuticals Ltd uso de rifaximina no tratamento de doenças do intestino
EP2781296B1 (de) 2013-03-21 2020-10-21 Corning Laser Technologies GmbH Vorrichtung und verfahren zum ausschneiden von konturen aus flächigen substraten mittels laser

Also Published As

Publication number Publication date
EP2252148B1 (en) 2019-03-20
KR20100122937A (ko) 2010-11-23
CA3300454A1 (en) 2026-03-02
RU2010139475A (ru) 2012-04-10
AU2009219240A1 (en) 2009-09-03
BRPI0908026B8 (pt) 2021-05-25
EP2252148A4 (en) 2014-02-26
US20130137713A1 (en) 2013-05-30
RU2519649C2 (ru) 2014-06-20
WO2009108814A1 (en) 2009-09-03
MX2010009197A (es) 2010-11-22
PT2252148T (pt) 2020-01-23
US8309569B2 (en) 2012-11-13
CN101959412A (zh) 2011-01-26
EP3563850A1 (en) 2019-11-06
US20110118295A1 (en) 2011-05-19
ES2727728T3 (es) 2019-10-18
EP2252148A1 (en) 2010-11-24
BRPI0908026A2 (pt) 2015-07-21
BRPI0908026B1 (pt) 2021-03-23
AU2009219240B2 (en) 2014-10-16
NZ587098A (en) 2012-09-28
RU2014104362A (ru) 2015-08-20
US20160000765A1 (en) 2016-01-07
DK2252148T3 (da) 2019-05-06
CA2716578A1 (en) 2009-09-03

Similar Documents

Publication Publication Date Title
PL2252148T3 (pl) Sposoby leczenia zespołu jelita drażliwego
PL2034844T3 (pl) Sposób leczenia biegunkowej postaci zespołu jelita drażliwego
BRPI0910854A2 (pt) métodos de tratamento
PL2733492T3 (pl) Sposób wykrywania nowotworów
EP2320045A4 (en) APPARATUS FOR TREATING EXHAUST GAS
ATE550415T1 (de) Waschzusammensetzung
BRPI0919116A2 (pt) método
BRPI1013317A2 (pt) método de cimentação
DK2300560T3 (da) Termisk behandling af biomasse
EP2276795A4 (en) Processing biomass
EP2262892A4 (en) EXPRESSION OF HETEROLOGOUS SEQUENCES
DK2293816T3 (da) Fremgangsmåder til behandling af reumatoid arthritis
BR112012005438A2 (pt) inibidores de vírus flaviviridae
EP2294227A4 (en) CONCENTRATION TEST
LT2318188T (lt) Medienos plokštės apdorojimo būdas
DK2313489T3 (da) Fremstillingsmetode
EP2349335A4 (en) LEVETIRACETAM IMMUNOASSAYS
BRPI0911625A2 (pt) Métodos
DK2453858T3 (da) Fremgangsmåde
BR112012004676A2 (pt) método de tratar infecções orotomixovirais.
BRPI0916597A2 (pt) Método
DK2501381T3 (da) Behandling af atrieflimmer
BRPI1014394A2 (pt) método de tratamento de vidro
CU23884B1 (es) Derivados de dibenzotiazepina
HRP20160577T1 (hr) Liječenje osteoartritisa